- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04444687
COVID 19: Is SARS-CoV-2 Contaminating Surgical Aerosols From Laparoscopy and Open Abdominal Surgery? (LapCoVIDSurg)
Is SARS-CoV-2 Contaminating Surgical Aerosols From Laparoscopy and Open Abdominal Surgery?
Study Overview
Detailed Description
The CoVID-19 pandemic has led to wide spread shut down of surgical services and restrictions to emergency procedures in most European countries and the United States. Next to concerns about resource limitations this has been justified by the risk of viral transmission during surgery. As to date the virus has been isolated from several body fluids with highest viral loads in the respiratory tract but also in feces. Aerosol producing interventions such as intubation have been proven to be a common source of health care worker infections in Italy and recently in the United Kingdom and the United States. The risk of surgical smoke and steam in open and laparoscopic surgery has been considered to bear similar risk but no data concerning these aerosols has been published so far and to the knowledge of the investigators no trials are under way (www.clinicaltrials.gov 5.4.2020). Only limited data has been available for other viral infections such as Hepatitis B and Human Papilloma Virus showing that surgical aerosols have the potential to carry such infectious particles. This rational has led to conflicting recommendations by surgical societies such as the Royal College of Surgeons or the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) to avoid laparoscopic procedures or use special filtration systems to evacuate the smoke and aerosols from the body cavity.
Since Switzerland and the city of Basel in particular currently have a high prevalence for CoVID 19 it is likely that surgeons will encounter patients with proven or suspected infection in the near future that require open or laparoscopic emergency surgical procedures. This offers the opportunity to collect a reasonable number of samples and smears from the abdominal cavity and surgical aerosols from these patients in limited time to answer the urgent question whether surgical smoke and aerosols of the abdominal cavity from CoVID-19 patients are contagious or not.
Investigators consider the trial to be a risk category A according to art 7 (HRO). There is no risk for patients included in this trial since the treatment of the patients will not differ from standard care. There will be no extra tests performed and only routine data will be collected. Specimen from laparoscopic smoke filters which are a protection device for medical staff will be tested on SARS-CoV-2 contamination.
Primary Objective:
The primary objective of the study is to investigate the contamination of surgical smoke and aerosols with SARS-COV-2 virus particles using the viral genome as a marker during laparoscopic and open abdominal emergency procedures for patients with suspected or proven infection.
Secondary objectives are to:
- assess the viral load in the peritoneal cavity and fluid
- compare viral load of smoke and aerosols in laparoscopic and open procedures
- assess possible transmission to surgeons during their service
Study Type
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age ≥ 18 years
- Proven or suspected (not ruled out) SARS-CoV-2 infection (at the time of surgery)
- Undergoing urgent or emergency laparoscopic or open abdominal surgery
- Able to provide informed general consent on further use of clinical data
Exclusion Criteria:
- Age < 18 years
- Unable to provide informed general consent & no possibility of informed general consent by proxy
- Recent (<24h) negative test for SARS-CoV-2
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
SARS-CoV-2-positive 01
SARS-CoV-2-positive patient, no symptoms, low viral load in tracheal aspirate, RNAemia not detectable
|
|
SARS-CoV-2-positive 02
SARS-CoV-2-positive patient, symptoms, high viral load in tracheal aspirate, RNAemia not detectable
|
|
SARS-CoV-2-positive 03
SARS-CoV-2-positive patient, symptoms, high viral load in tracheal aspirate, RNAemia detectable
|
|
Control
Control patients, SARS-CoV-2-negative
|
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
SARS-COV-2 RNA detection
Time Frame: Up to 12 months
|
The primary outcome will be SARS-COV-2 RNA detection in filter systems for surgical aerosols in laparoscopic surgery (YES/NO). If viral RNA can be detected, the aerosols should be considered contagious, and therefore the debate on protective measures for the surgical staff in case of emergency surgery and possibly delaying any urgent surgery to protect surgical teams would be reasonable. If viral RNA cannot be detected, the aerosols do not need to be considered contagious for SARS-CoV-2, and CoVID-19 patients could safely be considered for laparoscopic and open abdominal surgery if indicated. |
Up to 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Viral contamination of peritoneal cavity and fluid
Time Frame: Up to 12 months
|
Viral contamination of peritoneal cavity and fluid in laparoscopic cases (YES/NO)
|
Up to 12 months
|
Viral contamination of peritoneal cavity and fluid in open cases
Time Frame: Up to 12 months
|
Viral contamination of peritoneal cavity and fluid in open cases (YES/NO)
|
Up to 12 months
|
Viral infection of members of the surgical team
Time Frame: Up to 12 months
|
Viral infection of members of the surgical team (YES/NO)
|
Up to 12 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Marco von Strauss und Torney, Clarunis University Centre for Gastrointestinal and Liver Diseases
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 052020
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID
-
European Institute of OncologyFondazione I.R.C.C.S. Istituto Neurologico Carlo Besta; Azienda Ospedaliera... and other collaboratorsCompleted
-
Owlstone LtdCambridge University Hospitals NHS Foundation TrustCompleted
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Sultan Qaboos UniversityCompletedCOVID-19 | Non-CovidOman
-
Assiut UniversityRecruiting
-
Jilin UniversityUnknown
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Miami VA Healthcare SystemNot yet recruiting
Clinical Trials on Test for SARS-CoV-2
-
Instituto Brasileiro de Controle do CancerRecruitingSurgery | SARS-CoV-2 | OncologyBrazil
-
Manchester University NHS Foundation TrustCompletedCOVID-19 | Coronavirus InfectionUnited Kingdom
-
University of California, San FranciscoPatient-Centered Outcomes Research Institute; Kaiser PermanenteCompleted
-
Illumina, Inc.Helix OpCo, LLCCompletedSARS-CoV-2United States
-
Meshalkin Research Institute of Pathology of CirculationUnknown
-
Universidade Nova de LisboaRecruitingCoronavirus Infection | Pregnancy Complications | Breastfeeding | Neonatal Infection | Vertical Transmission of Infectious DiseasePortugal
-
LumiraDx UK LimitedCompletedCOVID-19 | Influenza A | RSV Infection | Influenza Type BUnited States
-
Stanford UniversityNational Institute of Allergy and Infectious Diseases (NIAID); National Institute...CompletedSARS-CoV-2 Acute Respiratory Disease | End-stage Renal Disease | Dialysis; ComplicationsUnited States
-
Universidade de Cabo VerdeUniversity of Southern Denmark; European and Developing Countries Clinical... and other collaboratorsCompletedCOVID-19 | SARS-CoV-2 | BCG | Health Care WorkerCape Verde
-
Assistance Publique - Hôpitaux de ParisPRODISS; WEEZEVENTCompleted